Marieke Griffioen

Leiden, ZH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications

Human CEBPA -N AML exhibits enhanced engraftment and a C/EBP α -p30-driven leukemic stem cell program.

Human CEBPA -N AML exhibits enhanced engraftment and a C/EBP α -p30-driven leukemic stem cell program.

Journal: bioRxiv : the preprint server for biology
Published: August 20, 2026

T-cell receptor repertoires against HLA class I-restricted minor histocompatibility antigens are highly diverse with a small subset of public clonotypes.

T-cell receptor repertoires against HLA class I-restricted minor histocompatibility antigens are highly diverse with a small subset of public clonotypes.

Journal: Journal for immunotherapy of cancer
Published: August 02, 2026

Comprehensive lincRNA Transcriptome in Acute Myeloid Leukemia: Integrating Known and Newly Identified lincRNAs Across Pediatric and Adult Cohorts.

Comprehensive lincRNA Transcriptome in Acute Myeloid Leukemia: Integrating Known and Newly Identified lincRNAs Across Pediatric and Adult Cohorts.

Journal: Non-coding RNA
Published: April 17, 2026

A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.

A T-cell receptor targeting RUNX1 frameshift mutations in acute myeloid leukemia.

Journal: Leukemia
Published: June 14, 2025

Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.

Resolving inter- and intra-patient heterogeneity in NPM1-mutated AML at single-cell resolution.

Journal: Leukemia
Published: January 29, 2025

Mutated DNMT3A creates a public HLADQ- binding neoantigen on acute myeloid leukemia.

Mutated DNMT3A creates a public HLADQ- binding neoantigen on acute myeloid leukemia.

Journal: Frontiers in immunology
Published: January 06, 2025

DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation.

DNA barcoded peptide-MHC multimers to measure and monitor minor histocompatibility antigen-specific T cells after allogeneic stem cell transplantation.

Journal: Journal for immunotherapy of cancer
Published: October 26, 2024

Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy.

Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy.

Journal: Journal for immunotherapy of cancer
Published: June 07, 2024

Ribosome profiling shows variable sensitivity to detect open reading frames for conventional and different types of cryptic T cell antigens.

Ribosome profiling shows variable sensitivity to detect open reading frames for conventional and different types of cryptic T cell antigens.

Journal: Molecular therapy. Methods & clinical development
Published: May 02, 2024

Hotspot DNA Methyltransferase 3A (DNMT3A) and Isocitrate Dehydrogenase 1 and 2 (IDH1/2) Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for Immunotherapy.

Hotspot DNA Methyltransferase 3A (DNMT3A) and Isocitrate Dehydrogenase 1 and 2 (IDH1/2) Mutations in Acute Myeloid Leukemia and Their Relevance as Targets for Immunotherapy.

Journal: Biomedicines
Published: March 13, 2024

Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation.

Minor histocompatibility antigens to predict, monitor or manipulate GvL and GvHD after allogeneic hematopoietic cell transplantation.

Journal: Best practice & research. Clinical haematology
Published: February 29, 2024

Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy.

Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy.

Journal: Molecular therapy. Methods & clinical development
Published: November 30, 2023
Showing 1-12 of 74

Last Updated: 09/26/2026